Mirae Asset Global ETFs Holdings’s RAPT Therapeutics RAPT Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,924	Closed	-$64.2K	–	3168
2025 Q4	$64.2K	Buy	+1,924	New	+$59.8K	﹤0.01%	2860
2025 Q2	–	Sell	-2,232	Closed	-$21.8K	–	3188
2025 Q1	$21.8K	Buy	2,232 +98	+5%	+$964	﹤0.01%	2975
2024 Q4	$27K	Buy	2,134 +95	+5%	+$1.21K	﹤0.01%	2978
2024 Q3	$32.8K	Buy	2,039 +209	+11%	+$4.23K	﹤0.01%	2981
2024 Q2	$44.7K	Buy	+1,830	New	+$84.5K	﹤0.01%	2815

Mirae Asset Global ETFs Holdings's RAPT Position: Q1 2026 in Review

Mirae Asset Global ETFs Holdings sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 1,924 shares — an estimated $64.2K sold.

Mirae Asset Global ETFs Holdings first reported a position in RAPT in Q2 2024 and held it in 5 quarters. The position peaked at $64.2K in Q4 2025. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.

Mirae Asset Global ETFs Holdings reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
Mirae Asset Global ETFs Holdings sold 1,924 RAPT Therapeutics shares in Q1 2026, an estimated $64.2K.
Mirae Asset Global ETFs Holdings first reported a position in RAPT Therapeutics in Q2 2024 and held it in 5 quarters.
Mirae Asset Global ETFs Holdings's RAPT Therapeutics position peaked at $64.2K in Q4 2025.
0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q1 2026, filed 15 May 2026.